MicroRNAs may hold the key to understanding why pulmonary hypertension presents differently in patients. A study presented at ESC 2025 compared microRNA expression in patients with idiopathic pulmonary arterial hypertension and those with Eisenmenger syndrome to uncover molecular differences underlying vascular remodeling. 

The study included 12 patients with idiopathic pulmonary arterial hypertension and 19 with Eisenmenger syndrome. Blood samples were analyzed for 754 microRNAs, and expression patterns were correlated with clinical measures such as natriuretic peptide levels and six-minute walk distances. Patients with idiopathic pulmonary arterial hypertension exhibited pronounced upregulation of pro-proliferative and anti-apoptotic microRNAs, whereas those with 

Eisenmenger syndrome showed higher levels of microRNAs linked to anti-inflammatory and endothelial-protective effects. Clinically, idiopathic pulmonary arterial hypertension patients had higher natriuretic peptide concentrations and reduced exercise capacity. Pathway analysis implicated transforming growth factor beta, hypoxia-inducible factor 1 alpha, and nuclear factor kappa B signaling in these differences. 

These findings highlight microRNA profiling as a promising strategy to differentiate pulmonary hypertension subtypes and guide targeted therapeutic approaches.